Develops T cell receptor-based immunotherapies for cancer and infectious diseases, aiming to provide targeted treatments with enhanced efficacy.
Immunocore Holdings plc is a pioneering biotechnology company focused on advancing immunotherapies to combat cancer, infectious diseases, and autoimmune disorders. Established in 1999 and headquartered in Abingdon, UK, Immunocore has achieved commercial-stage status with its groundbreaking treatment, KIMMTRAK, designed specifically for patients with unresectable or metastatic uveal melanoma. The company's robust pipeline includes promising candidates like IMC-C103C and IMC-F106C, currently undergoing Phase I/II trials across various solid tumor cancers such as NSCLC, gastric, ovarian, and more.
In the realm of infectious diseases, Immunocore is at the forefront with IMC-I109V, advancing through Phase I/II clinical trials for chronic hepatitis B virus. Additionally, IMC-M113V is in pre-clinical stages for potential treatment of human immunosuppression virus. The company also endeavors to develop precise, targeted immunotherapies tailored for autoimmune conditions. Immunocore's commitment to innovation and therapeutic advancement underscores its mission to address unmet medical needs and improve patient outcomes globally.
With a strong foundation in cutting-edge biotechnology, Immunocore combines scientific expertise with strategic partnerships to accelerate the development and commercialization of novel therapies. Through its comprehensive approach to harnessing the power of the immune system, Immunocore aims to redefine standards of care and pave the way for transformative treatments across multiple disease areas.